At Lorus, we are committed to our shareholders. We understand the needs of our investors and are committed to providing them with fair, timely and comprehensive information. In the following pages you will find financial news, reports and stock quotes to assist you. We have also provided information that will help you understand who we are and why we believe we are a company worthy of consideration for your portfolio.
If there is any additional information you require, or if you would like copies of any of the information contained herein, please contact Investor Relations.
Solid History and Management
Lorus has been in existence more than 20 years. It has a solid, stable senior management team and a well-rounded, loyal employee base. It has the expertise to develop products and it has the proven ability to deal with the adversity of a difficult Phase III clinical result, turning it into a potentially lucrative partnership opportunity.
Lorus Management is committed to not just making this company survive, but to flourish. Management’s focus is on bringing significant value to its shareholders and providing an exciting, supportive environment for its employees with a view to stimulating creativity, while providing effective near-term and long-term planning. With the support of a strong Board of Directors, loyal securityholders and a dedicated staff, management believes it can deliver on its strategy so that all will reap the benefits.
Robust Product Pipeline
Lorus currently has several products in various stages of development, from discovery to an advanced Phase II clinical program, which provide a succession of licencing and commercialization opportunities in the near and long term. We develop our product candidates with a focus on target-based cancer therapeutics that have excellent safety profiles and high therapeutic index. Our goal is to generate safe and efficacious drugs that have novel yet biologically sound mechanisms of action. We strive to achieve this goal by drawing on our ability to rapidly move drugs from discovery to advanced phases of clinical development and establishing strong strategic partnerships.
Lorus believes that the combined market potential for the Company’s current development stage products is more than $1 billion. In order to increase the likelihood of Lorus obtaining a significant share of this market, the Company pursues products that not only have the potential to work independently, but have the potential to work with and enhance the efficacy of other existing drugs.
Lorus continues to emphasize out-licensing through Phase II/III and opportunistically in-license promising candidate drugs as additions to the Company’s pipeline. We are extremely proud of our success in bringing the ZOR Pharma partnership to fruition, which has provided an opportunity for future revenues through potential milestones and royalty payments. The Company is currently pursuing partnerships or strategic alliances for its other late-stage products.
Lorus has a broad and diversified product portfolio. We apply our focused strategy of diversifying our risk and leveraging our strategic relationships to work towards executing a well-rounded, cost effective development strategy that brings products quickly through the development process to become prime candidates for partnership opportunities. We recognize that there are challenges to bringing products to market and therefore hedge our development activities by first looking at a variety of possible uses and then refining our development strategy based on the successful completion at each stage. Our product candidates are carefully chosen to be well-tolerated by cancer patients both to increase the commercialization potential of the product and, increase the quality of life for those patients and their families who are going through a difficult time.